- Home
- Companies
- usa new jersey
- therapeutic potential
Show results for
Refine by
Therapeutic Potential Suppliers Serving Usa New Jersey
37 companies found
based inAustin, TEXAS (USA)
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
based inVienna, AUSTRIA
Aposcience AG is a worldwide innovation leader in the field of regenerative medicine. Regenerative medicine has the potential to transform the treatment for diseases with high medical need, as the tissues afflicted by the disease process can be ...
based inSeattle, WASHINGTON (USA)
Impel Pharmaceuticals Inc. is a commercial stage pharmaceutical company focused on developing and providing transformative therapies that unlock the full potential of therapeutic molecules for people suffering from diseases with high unmet medical ...
Impel Pharmaceuticals has developed a proprietary drug delivery technology system that targets the vascular-rich upper nasal space,1 with multiple clinical trials suggesting rapid absorption and consistent drug bioavailability with ease of use in ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
IntegraSyn is InMed’s integrated cannabinoid synthesis system to manufacture pharmaceutical-grade cannabinoids. Our goal has always been to achieve an efficient, scalable, flexible and economical solution to produce cannabinoids with ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Somatic stem cell regenerative medicine utilizes somatic stem cells, which are present in various tissues of the body, with the aim of developing new treatments for diseases for which the current standard of care may be limited or unavailable to ...
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by ...
based inDallas, TEXAS (USA)
Berkshire Biomedical is developing a Revolutionary Secure Medication Delivery for the Intended User combined with a Physician-Enabled Management System. Secure Medication Delivery with Remote Monitoring and Compliance Support is the Most Efficient ...
based inNew York, NEW YORK (USA)
Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in ...
The field of bioconjugation has had a considerable impact on academic research, clinical diagnostics and the production of therapeutics. Peptides are an important type of molecules for derivatization by bioconjugation. ...
based inRedwood City, CALIFORNIA (USA)
Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has ...
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. The characteristics of ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inCambridge, MASSACHUSETTS (USA)
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal ...
based inNew Haven, CONNECTICUT (USA)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
based inCambridge, MASSACHUSETTS (USA)
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our ...
Sage stepped up to fill an innovation void by thinking differently about brain health disorders and how we approach the discovery and development of new ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...